Sweden
· Delayed Price · Currency is SEK SenzaGen AB Company Description
SenzaGen AB provides non-animal tests for assessing allergenicity.
The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment.
It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices; and substance based medical devices.
In addition, the company offers regulatory toxicity testing services, including skin corrosion, skin irritation, skin sensitization, and skin absorption; and eye irritation, phototoxicity, and genotoxicity testing services.
Further, it provides advisory services, such as pharma, medical devices, cosmetics, and chemical. The company offers services through license partners and distributors.
It has a collaboration agreement with the Research Institute for Fragrance Materials to develop tests for photosensitization.
SenzaGen AB was incorporated in 2010 and is headquartered in Lund, Sweden.
| Country | Sweden |
| Founded | 2010 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Peter Nahlstedt |
Contact Details
Address: Building 401 Lund, 223 81 Sweden | |
| Phone | 46 4 62 75 62 00 |
| Website | senzagen.com |
Stock Details
| Ticker Symbol | SENZA |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0010219626 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Peter Nahlstedt | President and Chief Executive Officer |
| Marianne Olsson | Vice President of Finance |
| Dr. Henrik Johansson | Chief Scientist |
| Tina Dackemark Lawesson | Vice President of Marketing and Communications |
| Andy Forreryd | Vice President of Sales |
| Helen Olsson | Vice President of Human Resources |